Aman Shah Abdul Majid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aman Shah Abdul Majid has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amin Malik Shah Abdul Majid
Department of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Malaysia
1 shared publication - Armaghan Shafaei
Edith Cowan University
1 shared publication Bassel Al Hindi
A School of Pharmaceutical Sciences , Universiti Sains Malaysia , Penang , Malaysia
1 shared publicationDoblin Sandai
B Advanced Medical and Dental Institute , Universiti Sains Malaysia , Penang , Malaysia
1 shared publicationElham Farsi
A School of Pharmaceutical Sciences , Universiti Sains Malaysia , Penang , Malaysia
1 shared publicationKameh Esmailli
A School of Pharmaceutical Sciences , Universiti Sains Malaysia , Penang , Malaysia
1 shared publication
Latest Publications
- 12 April 2016
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 39 (4) , 461-473
Mutagenicity and preclinical safety assessment of the aqueous extract ofClinacanthus nutansleaves
Context: Clinacanthus nutans (CN) is used traditionally for treating various illnesses. Robust safety data to support its use is lacking. Objective: To evaluate the adverse effects of aqueous extract of CN leaves (AECNL). Materials and methods: The oral toxicity of the AECNL was tested following Organisation for Economic Co-operation and Development (OECD) guidelines. Mutagenicity (Ames test) of AECNL was evaluated using TA98 and TA100 Salmonella typhimurium strains. Results: No mortality or morbidity was found in the animals upon single and repeated dose administration. However, significant body weight loss was observed at 2000 mg/kg during sub-chronic (90 d) exposure. In addition, increased eosinophil at 500 mg/kg and decreased serum alkaline phosphatase levels at 2000 mg/kg were observed in male rats. Variations in glucose and lipid profiles in treated groups were also observed compared to control. Ames test revealed no evidence of mutagenic or carcinogenic effects at 500 μg/well of AECNL. Conclusion: The median lethal dose (LD50) of the AECNL is >5000 mg/kg and the no-observed-adverse-effect level is identified to be greater than 2000 mg/kg/day in 90-d study.
- 12 April 2016
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 39 (4) , 461-473
Mutagenicity and preclinical safety assessment of the aqueous extract ofClinacanthus nutansleaves
Context: Clinacanthus nutans (CN) is used traditionally for treating various illnesses. Robust safety data to support its use is lacking. Objective: To evaluate the adverse effects of aqueous extract of CN leaves (AECNL). Materials and methods: The oral toxicity of the AECNL was tested following Organisation for Economic Co-operation and Development (OECD) guidelines. Mutagenicity (Ames test) of AECNL was evaluated using TA98 and TA100 Salmonella typhimurium strains. Results: No mortality or morbidity was found in the animals upon single and repeated dose administration. However, significant body weight loss was observed at 2000 mg/kg during sub-chronic (90 d) exposure. In addition, increased eosinophil at 500 mg/kg and decreased serum alkaline phosphatase levels at 2000 mg/kg were observed in male rats. Variations in glucose and lipid profiles in treated groups were also observed compared to control. Ames test revealed no evidence of mutagenic or carcinogenic effects at 500 μg/well of AECNL. Conclusion: The median lethal dose (LD50) of the AECNL is >5000 mg/kg and the no-observed-adverse-effect level is identified to be greater than 2000 mg/kg/day in 90-d study.